Time heals wounds Diabetes doesn’t know time

We are in a race against time to heal chronic wounds.

BioTissue Surgical products provide the natural healing properties of human birth tissue to the wound.

 

When Healing Time Matters, We’ve Got You Covered!

The annual incidence of Diabetic Foot Ulcers (DFUs) worldwide is between 9.1 to 26.1 million and up to 25% of those with diabetes will develop a foot ulcer.1,2 This poses extreme challenges to the U.S. healthcare system, spending $13.5M in medical costs towards diabetic patients every 30 minutes.3

Optimal treatment and management of foot ulcers is crucial in preventing life-threatening complications in diabetic patients. Adjunct therapy plays a critical role in treating and addressing the unique healing needs of diabetic patients with complex chronic wounds.

Learn More About the Healing Properties of Neox® 1K for Diabetic Foot Ulcers (DFUs) & Venous Leg Ulcers (VLUs):

By clicking the button below, I agree to receive marketing communications from BioTissue. I am aware that I can unsubscribe at any time.
This field is for validation purposes and should be left unchanged.
The Clock is Ticking

In Diabetes, Time to Healing Matters

The Neox® line of human amniotic membrane allografts are adjunct treatment modalities that help support regenerative healing and functional recovery for a variety of wounds—ranging from common surgical wounds to complex chronic diabetic foot ulcers, acute, partial, and full-thickness wounds.4-10

  • • Higher closure rates3-10
  • • Fewer applications3-10
  • • Reduced cost of care
  • • Expedited healing
Neox Family

Advanced Wound Care Products

01

Cryopreserved, ultra-thick human amniotic membrane allograft used as an adjunct treatment treatment for chronic, acute, partial, and full-thickness wounds.

02

Cryopreserved amniotic membrane allograft for wound applications, a thinner alternative to Neox 1K. The allograft is delivered on a non-implantable, gridded paper backing for easier handling and application.

03

A hydrated, room temperature, ultra-thick human amniotic membrane allograft derived from umbilical cord.

Neox: The Power of Innate Healing

by Alan J Block, DPM, MS, FASPS, FACFAS

In this educational webinar clip from our WoundCon Fall 2023 in-booth session, Dr. Alan Block shares his clinical experience in lower extremity wound healing with cryopreserved, ultra-thick human birth tissue allografts as an adjunct therapy to achieve optimal healing outcomes.

You can watch Dr. Block’s full webinar by signing up for our Physician Portal, which offers access to archived webinars on demand and serves as your one-stop-shop clinical resource center across all relevant medical sub-specialties.

Contact Us

To be connected with a local representative in your area, fill out the details below:

By clicking the button below, I agree to receive marketing communications from BioTissue. I am aware that I can unsubscribe at any time.
This field is for validation purposes and should be left unchanged.
References
Oliver TI, Mutluoglu M. Diabetic Foot Ulcer. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537328/.
Singh N et al. JAMA. Jan 12, 2005;293(2):217-28. doi:10.1001/jama.293.2.217.
Yang W, Dall TM, Beronjia K et al. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 2018; 41(5):917–928.
Voigt J, Ikeme S. Cost analysis comparing two human allogra s in healing diabe c foot ulcers over a 16 week period. Value Health. 2019; 22: S148-S9.
Caputo WJ, Vaquero C, Monterosa A, et al. Wound Repair Regen. 2016;24(5):885-893.
Couture M. Wounds. 2016;28(7):217-25.
Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetes Care 2002; 25: 1835–9.
Fife CE, Eckert KA, Carter MJ. Adv Wound Care 2018; 7: 77–94.
Raphael A. J Wound Care. 2016;25(Sup7):S10-17.
Raphael A, Gonzales J. J Wound Care. 2017;26(Sup10):S38-44.